study the effect of different concentrations of benzalkonium chloride on the ocular surface of non-dry-eyed patients post cataract surgery.
60 eyes of will be included in this study. * 20 eyes will receive regular Tobradex 0.1mg/ml BAK 5 times per day (Group 1). * 20 eyes will receive Dexathalm multidose 0.05mg/ml BAK 5 times per day (Group 2). * 20 eyes will receive single dose unit Dexathalm NO BAK 5 times per day (Group 3). Preoperative assessment: All selected patients will receive thorough explanation of the study design and aims, an informed consent will be obtained from all patients. Tear break up time (TBUT) will be measured non-invasively by Ocular Surface analyzer. Ocular Surface disease index will be calculated by filling a questionnaire. 12-item questionnaire provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. Postoperative: 1. All patients will be examined at day1, 1 week and 3 week postoperative. 2. At 3 weeks re-evaluate I. TBUT by non-invasive ocular surface analyzer II. OSDI by filling the questionnaire.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
KasrAl Ainy Hospital
Cairo, Giza Governorate, Egypt
NBUT
non invasive tear break up time
Time frame: preoperative and 1 month postoperative
TMH
Tear meniscus Height
Time frame: preoperative and 1 month postoperative
OSDI
ocular surface disease index
Time frame: preoperative and 1 month postoperative
MG loss
meibomian gland loss
Time frame: preoperative and 1 month postoperative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.